ECHELON-2, (NCT01777152), 5-year results of a randomised, double-blind, phase 3 study of frontline brentuximab vedotin plus CHP vs CHOP in patients with CD30-positive peripheral T-cell lyphoma L. Truemper, O. A. O'Connor, B. Pro, T. Illidge,R. Advani,N. L. Bartlett, J. H. Christensen,F. Morschhauser,E. Domingo-Domenech, G. Rossi, W. S. Kim,T. Feldman,T. Menne,D. Belada, A. Illes, K. Tobinai,K. Tsukasaki,S. P. Yeh, A. Huettmann,K. J. Savage,S. Yuen,S. Iyer,P. L. Zinzani,H. Miao, V Bunn, K. Fenton, M. Fanale, M. Puhlmann,S. HorwitzONCOLOGY RESEARCH AND TREATMENT（2021）引用 0|浏览6暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
